![]() |
|
|
Vol. 296, Issue 3, 697-703, March 2001
Pharmacology Laboratories, Institute for Drug Discovery Research,
Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Japan
In the present study the pharmacokinetics and pharmacodynamics of
tamsulosin were investigated in anesthetized male dogs. Hypogastric
nerve stimulation elevated the intraurethral pressure (IUP), which was
inhibited dose dependently by intraduodenal administration of
tamsulosin (3-30 µg/kg). The inhibition peaked about 90 min after
dosing and lasted up to 240 min. The basal mean blood pressure did not
change significantly during the observation period. The plasma,
prostatic, and urethral concentrations of tamsulosin were determined by
the liquid chromatography-mass spectrometry/mass spectrometry
method. The plasma concentration reached the maximal level within 30 min after dosing and gradually declined thereafter. The maximal total
plasma concentration of tamsulosin (Cmax, t) and its unbound concentration (Cmax, u)
correlated with the maximal effect on IUP response
[r2 = 0.81 (p < 0.01, n = 15) and
r2 = 0.84 (p < 0.01, n = 15), respectively]. Each individual
unbound plasma concentration did not correlate, however, with its
associated inhibition of IUP response
(r2 = 0.04, n = 126). Although the plasma concentration of tamsulosin decreased nearly
to the lower limit of quantitation 240 min after dosing, the prostatic
and urethral concentrations remained high, i.e., 13 to 44 times greater
than the plasma concentration. Our data demonstrate that the maximal
inhibition by tamsulosin of IUP response is well correlated with the
maximal plasma concentration in the early phase. The sustained effect
of tamsulosin on IUP response that follows may be related to prostatic
and urethral retention of tamsulosin.
This article has been cited by other articles:
![]() |
O. Parssinen, E. Leppanen, P. Keski-Rahkonen, T. Mauriala, B. Dugue, and M. Lehtonen Influence of tamsulosin on the iris and its implications for cataract surgery. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3766 - 3771. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Hancock, S. A. Buckner, M. E. Brune, T. A. Esbenshade, L. M. Ireland, S. Katwala, I. Milicic, M. D. Meyer, J. F. Kerwin Jr., and M. Williams Preclinical Pharmacology of Fiduxosin, a Novel alpha 1-Adrenoceptor Antagonist with Uroselective Properties J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 478 - 486. [Abstract] [Full Text] [PDF] |
||||